Recombinant HIV-1 virus with the indicated mutations in the protease gene. Mutations have been reported from drug resistant viral variants emerging in vivo, e.g. after treatment with the HIV protease inhibitor saquinavir
Recombinant HIV-1 plasmid (derived from pNL4-3) with the indicated mutations in the protease gene, which have been reported in the context of clinical drug resistance to HIV protease inhibitors.
Plasmid contains the entire genome of HIV-1 (NL4-3) with the respective specific mutations in the protease gene. These may confer drug resistance to specific HIV protease inhibitors and have been identified in clinical specimens from individuals with therapeutic failure.
Plasmid contains the entire genome of HIV-1 (NL4-3) with specific mutations in the protease gene, which can confer drug resistance to specific HIV-1 protease inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on protease inhibitors with virologic therapy failure.
proviral HIV-1 clone with an inserted TAATGA double stop codon in the endodomain of gp41 after position 8368 (NL4-3); (a stop codon at analogous position have been reported in early reports of SIV propagation in vitro.)
